文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

2021年乌克兰乙型、丙型和丁型病毒性肝炎血清标志物的全国代表性血清流行率

National representative seroprevalence of viral hepatitis B, C, and D seromarkers in Ukraine, 2021.
PubMed 文献 · Euro Surveill · 2025-01-01

乌克兰2021年基于横断面家庭SARS-CoV-2血清学调查的样本检测肝炎标志物,加权后抗-HCV为3.3%、抗-HBc为11.6%、HBsAg为0.9%,HBsAg阳性者中抗-HDV为7.5%;男性和南部地区HBV、HCV标志物流行率更高,提示终身暴露 substantial,需维持新生儿和高危人群HBV疫苗接种、常规筛查和早期治疗。

要点

  • 加权抗-HCV流行率为3.3%(95%CI:2.8-4.0),抗-HBc为11.6%(95%CI:10.8-12.5),HBsAg为0.9%(95%CI:0.7-1.2)。
  • HBsAg阳性者中抗-HDV阳性比例为7.5%(95%CI:3.0-17.9)。
  • 男性和乌克兰南部地区HBV及HCV血清标志物流行率更高。

核心结论

  • HBsAg流行率及相当高的抗-HBc和抗-HCV流行率表明存在大量终身暴露,强化了持续预防的必要性,如新生儿和高危人群HBV疫苗接种、常规乙型和丙型肝炎筛查、早期治疗及提高认识以减少持续传播。

研究设计与样本

  • 利用2021年乌克兰横断面家庭SARS-CoV-2血清学调查中可获得的血样,检测HCV抗体、HBV核心抗原总抗体(抗-HBc)、HBsAg和HDV抗体。
  • 采用基于乌克兰人口性别、年龄组和城市化水平分布的事后分层权重(逆概率加权)计算粗率和加权比例。
  • 计算HBsAg阳性者中抗-HDV阳性比例,并计算HBV和HCV血清标志物的加权地区估计值。

主要发现

  • 加权抗-HCV流行率为3.3%(95%CI:2.8-4.0),加权抗-HBc流行率为11.6%(95%CI:10.8-12.5),加权HBsAg流行率为0.9%(95%CI:0.7-1.2)。
  • HBsAg阳性个体中,7.5%(95%CI:3.0-17.9)为抗-HDV阳性。
  • 男性和乌克兰南部地区HBV及HCV血清标志物流行率更高。

临床怎么用

  • 作者结论指出,应维持新生儿和高危人群HBV疫苗接种、常规乙型和丙型肝炎筛查、早期治疗及提高认识以减少持续传播。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDAligned with World Health Organization (WHO) goals, Ukraine aims to eliminate viral hepatitis. While some data on viral hepatitis B and C prevalence exist among key populations, nationwide prevalence in the general population has never been assessed.AIMTo assess the prevalence of viral hepatitis B, C, and D seromarkers in Ukraine in 2021 to plan and monitor elimination measures.METHODSBlood samples available from a cross-sectional household-based SARS-CoV-2 serosurvey conducted in 2021 were tested for hepatitis C virus (HCV) antibodies, total antibodies against hepatitis B virus (HBV) core antigen (HBc), hepatitis B surface antigen (HBsAg) and hepatitis D virus (HDV) antibodies. We calculated crude and weighted proportions for anti-HCV, anti-HBc and HBsAg positivity. To account for differences in sex, age group and urbanisation level, we applied post-stratification weights using inverse probability weighting based on the distribution of the Ukrainian population. We calculated proportions positive for anti-HDV among HBsAg-positive cases and weighted regional estimates for HBV and HCV seromarkers.RESULTSWeighted prevalence of anti-HCV was 3.3% (95% CI: 2.8-4.0), anti-HBc 11.6% (95% CI: 10.8-12.5) and HBsAg 0.9% (95% CI: 0.7-1.2). Among HBsAg-positive individuals, 7.5% (95% СI: 3.0-17.9) were anti-HDV positive. We found higher prevalence of HBV and HCV seromarkers among men and in southern Ukraine.CONCLUSIONHBsAg prevalence and considerably high anti-HBc and anti-HCV prevalence indicate substantial lifetime exposure. This reinforces the necessity of sustained prevention such as HBV vaccination of newborns and groups at increased risk, regular hepatitis B and C screening, early treatment, and raising awareness to reduce ongoing transmission.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Kasatkina L, Fedorchenko V, Sidorova I, et al. National representative seroprevalence of viral hepatitis B, C, and D seromarkers in Ukraine, 2021. Euro Surveill. 2025. PMID: 40709475. doi:10.2807/1560-7917.ES.2025.30.29.2500015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。